Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world efficacy and safety of pomalidomide-rituximab-based combination therapy in newly diagnosed extranodal diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

QYQingsong YinHWHongfei WuHAHao Ai

Discussion

Loading...

Member takes

Implication

Retrospective analysis shows pomalidomide-rituximab improves complete response in newly diagnosed extranodal DLBCL patients, indicating safety and efficacy of the treatment.

Key Points

  • This analysis aims to evaluate the efficacy and safety of pomalidomide-rituximab in treating newly diagnosed extranodal DLBCL.
  • Eligible adult patients with extranodal DLBCL received pomalidomide-rituximab as first-line therapy.
  • Data were collected through retrospective chart review, including toxicities and responses to treatment.
  • Primary endpoints included overall response rate, complete response, and partial response.
  • The overall response rate was 92.9%, with a complete response rate of 64.3%.
  • Hematological adverse effects included neutropenia (71.4%) and anemia (14.2%).
  • The analysis involved 14 patients, with median follow-up of 6.74 months.

Cite This Study

Yin et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2b8https://doi.org/10.1182/blood-2025-7220
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A multicenter, single-arm study of camrelizumab combined with rituximab followed by R-CHOP as first-line treatment for young patients with primary extranodal diffuse large B-cell lymphoma: The credit trial2025
  2. 2Real-world outcomes of polatuzumab, rituximab, and lenalidomide in frail pts with diffuse large B-cell lymphoma.2026
  3. 3Efficacy and safety of pola-ICE, with or without rituximab in relapsed/refractory diffuse large B-cell lymphoma: A real-world multicenter study2025
  4. 4Pomalidomide, rituximab, and orelabrutinib in combination with polatuzumab vedotin for newly diagnosed diffuse large B-cell lymphoma in elderly, unfit, or frail patients:a prospective phase II study2025
  5. 5A real-world analysis of primary mediastinal large B-cell lymphoma: A single center study in China2025